Changes of Serum CTRP12 in Patients With Coronary Artery Disease After the Treatment of Percutaneous Coronary Intervention and Its Relationship With In-Stent Restenosis.

BACKGROUND: C1q/tumor necrosis factor-related protein 12 (CTRP12) plays a protective role in coronary artery disease (CAD) by reducing vascular inflammation. Whether CTRP12 could predict the occurrence of CAD and in-stent restenosis (ISR) occurrence after percutaneous coronary intervention (PCI) treatment remains unknown.

METHODS: This retrospective cohort study included patients with CAD who underwent PCI and had serum samples collected at baseline, 24 h, and 72 h post-PCI. The Gensini score was used to assess the severity of coronary artery stenosis. Serum CTRP12 levels were measured using an ELISA kit. Follow-up evaluation of ISR was performed using coronary angiography.

RESULTS: Serum CTRP12 levels were significantly lower in CAD patients than healthy controls (p < 0.001). A negative correlation was found between CTRP12 levels and both the Gensini score (r = -0.37, p < 0.001) and hs-CRP levels (r = -0.43, p < 0.001). Dynamic analysis revealed a significant reduction in CTRP12 levels 24 h post-PCI, with partial recovery observed at 72 h, although levels remained lower than baseline. Patients with ISR consistently demonstrated lower CTRP12 levels than those without ISR (NISR) at all time points. Receiver operating characteristic curve analysis indicated that CTRP12 levels at 24 h post-PCI exhibited the highest predictive accuracy for ISR occurrence.

CONCLUSION: Serum CTRP12 level may serve as a potential biomarker for diagnosing CAD and predicting ISR occurrence, with significant correlations to disease severity and dynamic changes after PCI.